Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.237 EUR | 0.00% | 0.00% | 0.00% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 43.51M | - | ||
+9.83% | 115B | B+ | ||
+10.80% | 105B | B+ | ||
-10.84% | 22.71B | B+ | ||
-1.46% | 21.83B | B | ||
-11.04% | 18.18B | A- | ||
-41.92% | 16.52B | A- | ||
-15.11% | 16.01B | B | ||
+6.62% | 14.14B | C+ | ||
+17.53% | 10.71B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABNX Stock
- Stock
- Ratings Cerenis Therapeutics